AzTrials
AzTrials

Vaccination ReactionNCT06023056

Hepatitis B Vaccination After Neonatal Surgery

An observational study of Vaccination Reaction and Hepatitis B Virus Infection, run by Children's Hospital of Chongqing Medical University at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant studies at home and abroad, and there is no corresponding guide or consensus. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Type of treatment
Vaccines
How many people
180 participants
Where
1 siteChina
Study dates
1 Nov 2022to 1 Nov 2030
How long will I take part?
2 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Follow up the neonates who live in the medical institution and meet the inclusion criteria. The end point of the study is 6 years after enrollment. Two mid-term evaluations will be conducted one year and two years after the start of the study. This project applies for funding until the mid-term evaluation of the first year. The follow-up research funds will be supported by the follow-up projects or self raised funds. The criteria for withdrawal from the cohort were: during the study period, the children were infected with hepatitis B virus due to other reasons such as "surgery, blood transfusion, trauma", or diagnosed with immune related diseases during the follow-up period.

Who may be able to join

  • 1. Term neonates; 2. Underwent staged gastrointestinal surgery; 3. HBsAg-; 4. No immune system disease; 5.no serious defect of heart, brain, liver, kidney and other organs.

Who cannot join

  • 1. Premature; 2. HBsAg+; 3. Having immune system diseases; 4. Having serious defect of heart, brain, liver, kidney and other organs; 5. Lost patients.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Hanbin Zhao, Doctor contact

18883370996

ddxek1994@outlook.com

yi wang, Doctor contact

17338332901

wy757311@hotmail.com

China1 site, 1 recruiting
  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400014

    Hanbin Zhao, 18883370996, ddxek1994@outlook.com

    Recruiting

Other trials in China

About this study

Official title: Influence of Delayed Vaccination of Hepatitis B Vaccine on Vaccination Safety and Immune Response of Newborns After Gastrointestinal Surgery

At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant studies at home and abroad, and there is no corresponding guide or consensus. In the early stage, our research team investigated the vaccination plans of the vaccination units in the main urban areas of Chongqing for such children through telephone follow-up, and found that the practices of each unit were different, all based on their own experience, and there was no clear evidence to support the vaccination or should not be vaccinated, which may cause some children to miss the best vaccination time or increase the risk of vaccination. The center is a relatively large neonatal surgery center in southwest China. The diagnosis and treatment of neonatal digestive tract malformations is at the leading level in China. It can carry out various neonatal operations such as neonatal necrotizing enterocolitis, congenital anorectal malformations, and congenital megacolon. On average, it carries out more than 30 third and fourth grade neonatal gastrointestinal operations every month. It has accumulated a lot of experience in the follow-up of newborns, There is a large amount of clinical data support for children who need to be vaccinated after surgery, so it is planned to follow up the second and third doses of hepatitis B vaccine and whether there are adverse reactions related to vaccination for children who need to be vaccinated after gastrointestinal surgery in the neonatal period, and at the same time check the production of HBsAb after vaccination, The immune response and adverse reactions of hepatitis B vaccine at different time points after surgery were studied to increase clinical evidence for the determination of hepatitis B vaccine vaccination program for newborns after surgery.

Read the detailed description

Research design

  1. Selection of research objects (research population)

Newborns who were screened in the department and met all of the following criteria were included in this study: 1) term infants and the first dose of hepatitis B vaccine had been vaccinated on time; 2) Children with indications for staged gastrointestinal surgery, and the first operation should be performed within 28 days after birth; 3) The child has no immune system disease or serious development defect or dysfunction of heart, brain, liver, kidney and other organs; 4) HBsAg - before initial operation; 5) Prenatal HBsAg - detection of the mother or father of the child; 6) The guardian signed the informed consent form and agreed to participate in the study. Exclusion criteria: 1) premature infants; 2) The first operation time exceeds 28 days after birth; 3) There are serious developmental malformations or dysfunction of heart, brain, liver, kidney and other organs or immune system diseases; 4) The patient or one of his parents is HBsAg+; 5) Children who are allergic to hepatitis B vaccine or have other serious adverse reactions; 6) Children interviewed by vector.

The end point of the study is 6 years after joining the group. Two mid-term evaluations will be conducted one year and two years after the start of the study. This project will apply for funding until the mid-term evaluation of the first year. The follow-up research funds will be supported by the follow-up projects or self raised funds. The criteria for withdrawal from the cohort were: during the study period, the children were infected with hepatitis B virus due to other reasons such as "surgery, blood transfusion, trauma", or diagnosed with immune related diseases during the follow-up period.

  1. Patient grouping
  2. Newborns who need to undergo gastrointestinal staging surgery as the research object can be included in this study after meeting the inclusion criteria and obtaining the consent of the guardian;
  3. The children included in this study were divided into "delayed vaccination group after surgery" and "standard vaccination group after surgery" according to the evaluation of the community vaccination department. At the same time, 1-year-old and 2-year-old children with indirect inguinal hernia who were vaccinated according to the standard immunization program and had no other diseases were taken as the "control group";
  4. Collect the general information of the "delayed vaccination group after operation" and the "standard vaccination group after operation", the mother's prenatal hepatitis B two-and-a-half, the children's hepatitis B vaccination time, the adverse reactions of hepatitis B vaccination, and the children's hepatitis B two-and-a-half before each hospitalization operation and at the age of 1 and 2; The level of hepatitis B surface antibody in delayed vaccination group, standard vaccination group and control group was compared;
  5. Collect the remaining serum of "Postoperative Delayed Inoculation Group" and "Postoperative Standard Inoculation Group" for HBV DNA detection;
  6. The definition of bias refers to ROBINS-I standard, including bias caused by confusion, bias in the selection of research objects, bias in the classification of intervention measures, bias deviating from the expected intervention measures, bias caused by missing data in the outcome measurement and bias in selective reporting of results. Bias is divided into four levels: mild, moderate, severe and extremely severe.
  7. Interventions

All the operated children were treated in Liangjiang Neonatal Surgery Department of Children's Hospital Affiliated to Chongqing Medical University. Before operation, they were examined for hepatitis B and HBV DNA.

  1. Follow up plan

Collect the general information of the "delayed vaccination group after operation" and the "standard vaccination group after operation", the mother's prenatal hepatitis B two-and-a-half, the children's hepatitis B vaccination time, the adverse reactions of hepatitis B vaccination, and the children's hepatitis B two-and-a-half before each hospitalization operation and at the age of 1 and 2; The level of hepatitis B surface antibody in delayed vaccination group, standard vaccination group and control group was compared; Collect the remaining serum of "Postoperative Delayed Inoculation Group" and "Postoperative Standard Inoculation Group" for HBV DNA detection;

  1. Main measurement indexes

Collect the general information of the enrolled children, the mother's two pairs and a half of hepatitis B before delivery, the children's hepatitis B vaccination time, the adverse reactions of hepatitis B vaccination, and the children's two pairs and a half of hepatitis B before each hospitalization operation and at the age of 1 and 2; The level of hepatitis B surface antibody in the delayed vaccination group, the standard vaccination group and the control group were compared.

  1. Sample size calculation

According to the previous statistics, the average value of HBsAb of 992 neonates in our outpatient department was 349.5 IU/L, the standard deviation was 420.59 IU/L, and the average value of HBsAb of 1317 1-year-old children was 575.5 IU/L. Therefore, it is estimated that HBsAb will increase by 226 IU/L during the 1-year follow-up α= 0.05, β= 0.1, calculated according to the following formula.

Data management

  1. Data entry This project uses EpiData to establish the database. The database designer determines the database creation requirements and database structure according to the case report form (CRF form) to ensure that the database content and structure are consistent with the CRF form, and the specified data can be properly entered into the database. The xx database is strictly password protected, and only the personnel directly involved in the research can obtain the password/account. According to the original observation records of the subjects, the researchers timely, completely, correctly and clearly loaded the data into the CRF table. The CRF form reviewed and signed by the investigator shall be submitted to the clinical research data administrator in time. The research data are entered into the EpiData database by authorized researchers. The database system of EpiData is used for double person and double computer input, and then the database is compared twice. Data changes due to input errors or other reasons will be recorded in detail and confirmed by the researcher. The questions and answers between the data administrator and the researcher are in the form of question table, which is kept for future reference.
  2. Contents and methods of data verification and management Key points and process of data verification, as well as requirements for data locking. For example, when all case report forms have been entered in duplicate and checked without error, data cleaning has been completed, all queries have been answered or explained, and data quality control has been completed, the data administrator will write a database inspection report, which includes the completion of the study (including the list of dropped subjects), inclusion/exclusion criteria, integrity check, logic consistency check, outlier data check, time window check, drug combination check Adverse event inspection, etc. The researcher confirmed that the database will be locked.
  3. Safety evaluation All adverse events were recorded. In particular, incidents that resulted in hospitalization, prolonged hospitalization, additional surgical or medical treatment, or death were reported.
  4. Quality control and quality management

Before the start of the study, patients were enrolled in strict accordance with the inclusion and exclusion criteria, standardized case report forms (CRF) were developed, and ethical review and clinical study registration were confirmed; During the research, ensure the integrity of CRF table data records, the consistency of original data and CRF data, the security of data archiving, review the completion progress and queue interruption, and analyze the preciseness of data; After the study, confirm the integrity of statistical data, the standardization of statistical methods, the standardization of paper writing, and update the clinical study registration data.

Keywords
Hepatitis B Vaccination Reaction, Hepatitis B Vaccine Adverse Reaction, Neonatal surgery, Gastrointestinal Surgery
Medical subject headings
Hepatitis B, Transfusion Reaction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06023056
Study groupRoleWhat they receive
Delayed vaccination group after gastrointestinal surgeryNewborns undergoing gastrointestinal surgery are delayed from receiving hepatitis B vaccination in the vaccination institutions due to the impact of surgery.
The group of vaccination on time after gastrointestinal surgeryNewborns undergoing gastrointestinal surgery shall be vaccinated with hepatitis B vaccine on time by vaccination institutions.
Control groupChildren who are free of disease and have vaccination and physical examination on time.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prenatal hepatitis B surface markers

    Prenatal hepatitis B surface makers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) of mothers and childrens. Measurement of relevant indicators using Roche chemiluminescence method.

    Measured: 1 month

  2. Newborn condition

    Surface markers of hepatitis B (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) in newborn.

    Measured: 1 month

  3. Vaccination time

    Time for subjects to receive three doses of hepatitis B vaccine

    Measured: up to 2 years

  4. Adverse reactions

    Whether there are vaccine related adverse reactions after vaccination: fever, urticaria, local pain, erythema, induration, atc.

    Measured: 2 years

  5. Immune effect of vaccine

    Results of hepatitis B surface markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) at the age of 1 and 2

    Measured: up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2023
  2. Study start1 Nov 2022
  3. Primary completion1 Nov 2030 (estimated)
  4. Study completion1 Nov 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
180 participants (estimated)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06023056
Sponsor's protocol ID
chcmuzhb20221114
Status last verified
Sep 2023
First submitted
29 Nov 2022
Last updated
11 Sep 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We will decide whether to open the case according to the willingness to finally include the case.

Publications

  • National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 28;60(2):1-64.

    PubMed 21293327
  • Szilagyi PG, Rodewald LE. Missed opportunities for immunizations: a review of the evidence. J Public Health Manag Pract. 1996 Winter;2(1):18-25. doi: 10.1097/00124784-199600210-00005.

    PubMed 10186652

Questions about this trial

What is this clinical trial studying?

An observational study of Vaccination Reaction and Hepatitis B Virus Infection, run by Children's Hospital of Chongqing Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hanbin Zhao, Doctor (18883370996, ddxek1994@outlook.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prenatal hepatitis B surface markers (time frame: 1 month). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06023056, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in